Get started
Author

Sharon Anneve Glynn

Observed names: Glynn, Sharon A, Glynn, Sharon A., S A Glynn, S Glynn, S. A. Glynn, S. Glynn, S.A. Glynn, SA Glynn, Sharon A. Glynn, Sharon A Glynn, Sharon A. Glynn, Sharon Glynn
Observed institutions: National Institutes of Health, The University of Texas MD Anderson Cancer Center, Science Foundation Ireland, National University of Ireland, Ollscoil na Gaillimhe – University of Galway, University of Milan, United States Army Medical Research Institute of Infectious Diseases, University Hospital Galway, National Cancer Institute, Center for Cancer Research, Dublin City University, The University of Texas Health Science Center at Houston
ORCID: 0000-0003-1459-2580
Observed ORCID: 0000-0003-1459-2580
OpenAlex ID: A5017672961
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
2020 · Merryn Voysey, Sue Ann Costa Clemens, et al. · The Lancet · 4,723
PDF
Mesenchymal stem cells: key players in cancer progression
2017 · Sarah M. Ridge, Francis J. Sullivan, et al. · Molecular Cancer · 541
PDF
The yin and yang of nitric oxide in cancer progression
2013 · A. J. Burke, F. J. Sullivan, et al. · Carcinogenesis · 386
PDF
Increased NOS2 predicts poor survival in estrogen receptor–negative breast cancer patients
2010 · Sharon A. Glynn, Brenda J. Boersma, et al. · Journal of Clinical Investigation · 259
The Role of Nitric Oxide in Cancer: Master Regulator or NOt?
2020 · Faizan H. Khan, Eoin Dervan, et al. · International Journal of Molecular Sciences · 204
PDF
Immunotherapeutic Potential of Anti-Human Endogenous Retrovirus-K Envelope Protein Antibodies in Targeting Breast Tumors
2012 · Feng Wang-Johanning, Kiera Rycaj, et al. · JNCI Journal of the National Cancer Institute · 185
PDF
Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression
2014 · Julie L. Heinecke, Lisa A. Ridnour, et al. · Proceedings of the National Academy of Sciences · 179
Signaling and stress: The redox landscape in NOS2 biology
2015 · Douglas D. Thomas, Julie L. Heinecke, et al. · Free Radical Biology and Medicine · 152
PDF
Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment—Poor Prognosis or New Therapeutic Opportunity
2012 · Lisa A. Ridnour, Robert Y.S. Cheng, et al. · Clinical Cancer Research · 152
PDF
S-Nitrosylation of EGFR and Src Activates an Oncogenic Signaling Network in Human Basal-Like Breast Cancer
2012 · Christopher H. Switzer, Sharon A. Glynn, et al. · Molecular Cancer Research · 145
Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice?
2014 · Ronan F. Downey, Francis J. Sullivan, et al. · International Journal of Cancer · 141
PDF
MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer
2012 · R S Hudson, M Yi, et al. · Oncogene · 125
Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer
2017 · Debashree Basudhar, Sharon A. Glynn, et al. · Proceedings of the National Academy of Sciences · 114
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells
2008 · Sharon A Glynn, Dermot O'Sullivan, et al. · BMC Cancer · 110
PDF
Expression of Human Endogenous Retrovirus Type K Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer
2011 · J. Zhao, K. Rycaj, et al. · Genes & Cancer · 105
The Specificity of Nitroxyl Chemistry Is Unique Among Nitrogen Oxides in Biological Systems
2011 · Wilmarie Flores-Santana, Debra J. Salmon, et al. · Antioxidants and Redox Signaling · 103
Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers
2014 · Tiffany A. Wallace, Ronan F. Downey, et al. · Carcinogenesis · 96
PDF
Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways
2017 · Pablo Garrido, Aliaa Shalaby, et al. · Oncotarget · 95
PDF
Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer
2012 · Christopher H Switzer, Robert Y-S Cheng, et al. · Breast Cancer Research · 93
PDF
Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression
2016 · Debashree Basudhar, Veena Somasundaram, et al. · Antioxidants and Redox Signaling · 92
COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer
2010 · Sharon A Glynn, Robyn L Prueitt, et al. · BMC Cancer · 80
PDF
Proteomic analysis of isolated membrane fractions from superinvasive cancer cells
2006 · Paul Dowling, Paula Meleady, et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 77
Nitric Oxide Synthase and Breast Cancer: Role of TIMP-1 in NO-mediated Akt Activation
2012 · Lisa A. Ridnour, Kimberly M. Barasch, et al. · PLoS ONE · 75
PDF
Targeting Nitric Oxide: Say NO to Metastasis
2022 · Tejaswini P. Reddy, Sharon A. Glynn, et al. · Clinical Cancer Research · 74
PDF
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer
2011 · Christopher H. Switzer, Sharon A. Glynn, et al. · Trends in Pharmacological Sciences · 74
PDF
Works count: 190
Citation count: 9,519
H-index: 36
I10-index: 61
Year
Topic
Type